Today’s guest on the podcast is Marc Bernegger, a serial tech entrepreneur who has been following developments in the field of longevity since 2009. Recently he became a founding partner of the Swiss company, Maximon, whose core missions is building companies and providing support to longevity entrepreneurs.
Marc has worked for over a decade between two continents at this point, and his interest in longevity has never been more intense. From aging skin to gut microbiomes, there’s a lot of work and research left to do, and if you’re of Bernegger’s school of thought, longevity is a matter of the present, rather than some notion about the distant future. As you will hear today, Marc is like so many others in his field - putting in the work now to create a better tomorrow.
The Finer Details of This Episode:
- Entrepreneurial support
- Maintaining a growing company
- The future of aging skin
- Cooperation in the longevity biotech sector
- Investment attitudes in the US and Europe
- Seeing longevity as a present issue
Quotes:
“Our ambition is to only focus on businesses where there's a real scientific background, so not selling snake oil, which is maybe on the short term very profitable but definitely not sustainable.”
“We support them from day one. We help them with all our network experiences and learnings as serial entrepreneurs ourselves. We support them with money. And we really try to be a sparring partner without maybe becoming too annoying.”
“I think for me as an entrepreneur, that's always very fulfilling that you can give, be an alternative, and create more entrepreneurs starting companies.”
“One of the reasons we decided to launch Maximon as a company builder is that we wanted to show that it’s possible to monetize the megatrend of longevity as we speak.”
“You can really boost and accelerate the growth by combining some of the different business models.”
“By having more elderly, healthy, longer living people, a lot of business models will change. So elderly living is a big topic. Something we're looking into is the whole gut microbiome, but also microbiome in other areas where you have a huge impact on longevity.”
“The longevity biotech sector, even in the regulated drugs space, is pretty cooperative. We don't think of ourselves as competitors, because everyone wants everyone else to succeed.”
Links:
Email questions, comments, and feedback to podcast@bioagelabs.com
Translating Aging on Twitter: @bioagepodcast
BIOAGE Labs Website BIOAGELabs.com
BIOAGE Labs Twitter @bioagelabs
BIOAGE Labs LinkedIn
Maximon Homepage
